AFP and neoplasm: For patients receiving systemic treatment, multivariate analysis identified the tumor stage (BCLC B: HR: 5.2, 95% CI: 1.40–19.3; p = 0.014; BCLC C; HR: 8.23; 95% CI: 2.53–26.8; p = < 0.001) and an AFP level between 200–399 ng/mL (HR: 6.43, 95% CI: 1.43–29.0; p = 0.015) as risk factors for impaired survival (Figure 3B).